Fairvalue-Calculator Fairvalue-Calculator
EN DE

Oruka Therapeutics, Inc (ORKA) Fair Value & Analysis

Healthcare · US · Market cap $3.3B

Price$83.40
Fair Value$35.21
Upside-57.8%
Quality91/100
Evidence: Low Range $26.41 – $44.01

Fair value as of: Jun 24, 2026

Analysis

Oruka Therapeutics, Inc (ORKA) currently trades at $83.40, while our model-based Fair Value estimate is $35.21 — implying the stock looks roughly 57.8% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Oruka Therapeutics, Inc (ORKA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $35.21 versus a price of $83.40 — about −58% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ORKA?
Our 21-model fair value for Oruka Therapeutics, Inc is $35.21 (as of Jun 24, 2026), built from audited fundamentals. The current price is $83.40.
What is the quality score of ORKA?
Oruka Therapeutics, Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.